AR anomalies are associated with shorter time on subsequent hormone therapy. In a preliminary analysis of the SPARTAN study, blood samples were collected at baseline and at the end of study treatment (at the time of an event):1
- ERLEADA® + ADT does not preferentially increase the frequency of AR anomalies commonly associated with AR signaling resistance in mCRPC vs placebo + ADT
- No mechanisms of resistance have been observed with ERLEADA® + ADT vs placebo + ADT
FREQUENCY OF AR ANOMALIES AT BASELINE vs END OF STUDY TREATMENT††6
REFERENCE :
1- Smith MR, et al. Poster presented at the 2018 American Association for Cancer Research Annual Meeting, 14–18 April, 2018, Chicago, IL, USA.
1- Smith MR, et al. Poster presented at the 2018 American Association for Cancer Research Annual Meeting, 14–18 April, 2018, Chicago, IL, USA.
CP-142079
